toripalimab
Shanghai Junshi Bioscience,coherus
['toripalimab', 'choice-01']
dr. lin wu presents final os from choice-01: phase iii study of toripalimab vs placebo with 1l chemotherapy at #asco23. final os hr 0.73; mos 23.8m vs 17.0m; 3y os rate 32.5% vs 18.4% - all despite high crossover rate (65% in placebo had subsequent pd1 therapy). 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown, Co-Host Official @IASLC Podcast, #ITYSL, #HereWeGo